Background and Aims: Delayed diagnosis and treatment of tuberculosis (TB) contribute to poor outcomes, especially for endobronchial TB (EBTB), which typically leads to tracheobronchial stenosis. Finding rapid and accurate diagnostic tools for EBTB is crucial. GeneXpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) was recommended by the World Health Organization (WHO) as a standard molecular biological diagnostic technique for MTB. The aim of this study was to evaluate the efficacy of GeneXpert MTB/RIF for diagnosing EBTB and for evaluating RIF resistance.
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Methods: Biopsy tissue and bronchial brushings from EBTB patients were prospectively assessed with GeneXpert MTB/RIF. The diagnostic yields of auramine O-stained sputum smears and bronchial brush smears were obtained, and the results were compared with the cultures of sputum and biopsy tissues for MTB.
Results:
In 61 confirmed cases of EBTB, the sensitivities of sputum smear, bronchial brush smear, sputum culture and tissue culture to diagnose EBTB were 13.1%, 32.8%, 36.1% and 68.9%, respectively. For bronchial brushings and biopsies, our data showed sensitivities of 57.4% and 63.9%, respectively, and a specificity of 100% for GeneXpert MTB/RIF, and these results were superior to those of sputum smears, bronchial brush smears and sputum culture. GeneXpert MTB/RIF for bronchial brushings and biopsies showed complementarity in its diagnostic performance. Resistance to RIF was identified in 17.4% (8/46) of GeneXpert MTB-positive cases.
Conclusion:
GeneXpert MTB/RIF may enable more rapid EBTB diagnosis and determination of RIF resistance, which are crucial for timely treatment. Devices Agency in 2014. Although delamanid has been widely used in Japan, its efficacy and safety in the real world remain uncertain.
Methods: We retrospectively evaluated 10 pulmonary MDRTB patients for whom treatment with regimens including delamanid was started between 2014 and 2017. Treatment outcomes were defined as cure, culture conversion, failure or death.
Results: Mean age of patients was 59.7 years, and 7 patients were male. Six patients had cavitary disease. Drug sensitivity testing showed that two patients had extensively drug-resistant tuberculosis. Two adverse events were reported; QT prolongation requiring discontinuation and mild peripheral neuropathy. Delamanid could be administered as long as 18 months in 3 patients. Overall treatment outcomes were 3 cured, 5 culture conversion and 2 died. Bacteriological success was achieved in 90% (9/10) patients including one patient died of cerebral haemorrhage.
Conclusion: Delamanid has a considerable efficacy for treating pulmonary MDRTB with acceptable safety profile. and ionomycin. The responses were measured by flow cytometry, and we analyzed the inter-group difference.
Results: The age and sex as well as the average percentages of CD4 and CD8 T cells were similar among the three groups. Between the patients with MAC-LD and the controls, the MAC-related TNF-α+ cells (with or without other cytokine expression) on CD8+ T cells were higher in the patient with MAC airway colonization than those with MAC-LD (36.2% vs 27.5%, p = 0.021 by Mann Whitney U test). In stimulation with PMA plus ionomycin, IL-2 single positive CD8 T cells was higher in MAC-LD than that in MAC airway colonization. comparing with MAC-PD and airway colonization (6.4% vs 3.4%, P = 0.024). The percentage of MACspecific CD8+ all TNF-α+ and super-antigen induced CD8+ single IL-2+ could have good performance to predict MAC pulmonary infection from airway colonization by ROC curve (the AUC: 0.748, P = 0.008). 
Conclusion

